2020 revenue: $1.051B (–10%)
Headquarters: San Diego
Despite the COVID-19 pandemic and its revenue effects, NuVasive made investments in infrastructure, talent and innovation to enable the company to thrive over the long term, CEO J. Christopher Barry explained in the minimally invasive spine surgery tech company’s fourth-quarter earnings announcement in February. The company increased R&D investment by more than 10% in 2020. In February, NuVasive spent $150 million to acquire Simplify Medical and its Simplify Cervical Artificial Disc for cervical total disc replacement (cTDR) to add to the company’s new C360 cervical portfolio.
The Simplify disc received FDA approval for two-level cTDR in April. NuVasive points out that it’s only one of three approved devices for the procedure. Next, the company is driving toward a summer, global launch of its Pulse platform, an integrated technology platform to enable better spine surgery.